CT52923 - ≥98% , CAS No.205256-55-9

CAS: 205256-55-9 Cat. No.: C650187 Fórmula: C23H25N5O4S Peso molecular: 467.54
Disponível para encomenda
GRAU & PUREZA ≥98%
Storage
Protected from light,Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Tamanho
Alemanha (EU)
USA*
Preço
Qtd
5mg
C650187-5mg
Sob encomenda · 8–12 semanas
156,97€
10mg
C650187-10mg
Sob encomenda · 8–12 semanas
243,75€
25mg
C650187-25mg
Sob encomenda · 8–12 semanas
486,71€
50mg
C650187-50mg
Sob encomenda · 8–12 semanas
781,75€
100mg
C650187-100mg
Sob encomenda · 8–12 semanas
1180,91€
Enter a quantity for the sizes you want to add.

Visão geral

CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.

In Vitro

CT52923 inhibit the PDGFRs and stem cell factor receptor with an IC 50 value of 100 to 200 nM. CT52923 (0.01-30 μM; 24 h) blocks plateletderived growth factor-induced smooth muscle cell migration or fibroblast proliferation with an IC 50 of 64 and 280 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Migration AssayCell Line: Rat A10 smooth muscle cells Concentration: 0.01-30 μM Incubation Time: 24 h Result: Inhibited PDGF-induced cell migration with an IC 50 of 64 nM.

In Vivo

CT52923 (oral; 5, 15, 30, and 50 mg/kg; twice daily) can significantly inhibit neointima formation following carotid artery injury by oral administration in the rat . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat carotid artery balloon angioplasty model . Dosage: 5, 15, 30, and 50 mg/kg Administration: Oral gavage; twice daily Result: Inhibited PDGF-mediated response to vascular injury.

Form:Solid

Especificações

Especificações e pureza
≥98%
Mecanismos bioquímicos e fisiológicos
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomeruloneph
Condições de armazenamento de armazenamento
Protected from light,Store at -80°C
Enviado em
Dry ice packs + Cold packs
Este produto requer transporte de cadeia fria. Serviços terrestres e outros serviços econômicos não estão disponíveis.
Tipo de ação
ANTAGONIST
Pureza
≥98%
Nomes e identificadores
Peso molecular
467.54

Dados avançados

Certificados(CoA,COO,BSE/TSE e Mapa de Análise)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculadoras de soluções
Revisões

Avaliações dos Clientes

Deseja que lhe enviemos uma mensagem quando tivermos descontos disponíveis?

Lembrar-me mais tarde

Obrigado! Por favor, verifique a sua caixa de entrada de e-mail para confirmar.

Ops! As notificações estão desativadas.